Düsseldorf, Germany April 18, 2017.
ImmunoQure AG, a German biotechnology company focused on the development of autoantibodies as therapeutics to treat common human diseases today announced the publication of data in the leading scientific journal The Journal of Experimental Medicine. In a Worlds-first, the authors have developed a system by which interferon-α (IFNα) levels can be measured in serum, plasma and cerebrospinal fluid. Interferon was identified over 60 years ago but could not be directly measured until now because it is present in such small amounts, indicating how powerful a cytokine it is. Furthermore, Interferon plays a fundamental role in health and disease.
Using single-molecule array (Simoa) digital ELISA technology, the authors recorded attomolar (10-18mol) concentrations of IFNα in healthy donors, viral infection, and complex and monogenic interferonopathies.